Importer of Controlled Substances Application: Biopharmaceutical Research Company

Issuing agencies

Abstract

Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 163 (Tuesday, August 25, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 163 (Tuesday, August 25, 2026)]
[Notices]
[Pages 54883-54884]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-17276]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1748]


Importer of Controlled Substances Application: Biopharmaceutical 
Research Company

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Biopharmaceutical Research Company has applied to be 
registered as an importer of basic class(es) of controlled 
substance(s). Refer to Supplementary Information listed below for 
further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants, therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
September 24, 2026. Such persons may also file a written request for a 
hearing on the application on or before September 24, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be

[[Page 54884]]

aware that submitted comments are not instantaneously available for 
public view on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. If you have received a 
Comment Tracking Number, your comment has been successfully submitted 
and there is no need to resubmit the same comment. All requests for a 
hearing must be sent to: (1) Drug Enforcement Administration, Attn: 
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 
22152; and (2) Drug Enforcement Administration, Attn: DEA Federal 
Register Representative/DPW, 8701 Morrissette Drive, Springfield, 
Virginia 22152. All requests for a hearing should also be sent to: Drug 
Enforcement Administration, Attn: Administrator, 8701 Morrissette 
Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on July 14, 2026, Biopharmaceutical Research Company, 
11045 Commercial Parkway, Castroville, California 95012-3209, applied 
to be registered as an importer of the following basic class(es) of 
controlled substance(s):

------------------------------------------------------------------------
                                          Drug
          Controlled substance            code           Schedule
------------------------------------------------------------------------
Marihuana Extract......................    7350  I
Marihuana..............................    7360  I
Tetrahydrocannabinols..................    7370  I
------------------------------------------------------------------------

    The company plans to import the listed controlled substances as 
flowering plants and cannabis derivatives to support analytical 
chemistry analyses, research and the manufacturing of dosage forms for 
preclinical and clinical trials. No other activities for these drug 
codes are authorized for this registration.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of Food and Drug Administration-approved or non-approved finished 
dosage forms for commercial sale.

Justin Wood,
Acting Deputy Assistant Administrator.
[FR Doc. 2026-17276 Filed 8-24-26; 8:45 am]
BILLING CODE P


</pre></body>
</html>